Towards the implementation of quality by design to the production of therapeutic monoclonal antibodies with desired glycosylation patterns
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Quality by design (QbD) is a scheme for the development, manufacture, and approval of pharmaceutical products. The end goal of QbD is to ensure product quality by building it into the manufacturing process. The main regulatory bodies are encouraging its implementation to the manufacture of all new pharmaceuticals including biological products. Monoclonal antibodies (mAbs) are currently the leading products of the biopharmaceutical industry. It has been widely reported that glycosylation directly influences the therapeutic mechanisms by which mAbs function in vivo. In addition, glycosylation has been identified as one of the main sources of monoclonal antibody heterogeneity, and thus, a critical parameter to follow during mAb manufacture. This article reviews the research on glycosylation of mAbs over the past 2 decades under the QbD scope. The categories presented under this scope are: (a) definition of the desired clinical effects of mAbs, (b) definition of the glycosylation‐associated critical quality attributes (glycCQAs) of mAbs, (c) assessment of process parameters that pose a risk for mAb glycCQAs, and (d) methods for accurately quantifying glycCQAs of mAbs. The information available in all four areas leads us to conclude that implementation of QbD to the manufacture of mAbs with specific glycosylation patterns will be a reality in the near future. We also foresee that the implementation of QbD will lead to the development of more robust and efficient manufacturing processes and to a new generation of mAbs with increased clinical efficacy. © 2010 American Institute of Chemical Engineers Biotechnol. Prog., 2010
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835
Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation
Kaneko, Y., Nimmerjahn, F., & Ravetch, J. V. (2006) · Science · doi:10.1126/science.1129594 · Cited by 1,754
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
Chung, C. H., Mirakhur, B., Chan, E., Le, Q.-T., Berlin, J., Morse, M., Murphy, B. A., Satinover, S. M., Hosen, J., Mauro, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074943 · Cited by 1,521
Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210665200 · Cited by 1,413 · cited 1×
“However, it was later observed that the addition of bisecting GlcNAc residues increased ADCC by competing with the addition of fucose to the oligosaccharide structures.(54) Additional Figure 2.”
BackgroundRecapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc
Anthony, R. M., Nimmerjahn, F., Ashline, D. J., Reinhold, V. N., Paulson, J. C., & Ravetch, J. V. (2008) · Science · doi:10.1126/science.1154315 · Cited by 849
Glycosylation as a strategy to improve antibody-based therapeutics
Jefferis, R. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2804 · Cited by 829
Umaña, P., Jean–Mairet, J., Moudry, R., Amstutz, H., & Bailey, J. E. (1999) · Nature Biotechnology · doi:10.1038/6179 · Cited by 764 · cited 1×
“The early efforts to increase ADCC by glycan engineering were based on over-expressing genes for GnTIII,(56) which is the sugar-transfer enzyme that adds bisecting GlcNAc to the core mannose of the oligosaccharide.(56) At that time, it was thought that the presence of bisecting GlcNAc on IgG1based mAbs contributed to…”
BackgroundYamane‐Ohnuki, N., Kinoshita, S., Inoue‐Urakubo, M., Kusunoki, M., Iida, S., Nakano, R., Wakitani, M., Niwa, R., Sakurada, M., Uchida, K., et al. (2004) · Biotechnology and Bioengineering · doi:10.1002/bit.20151 · Cited by 572
Humanization of yeast to produce complex terminally sialylated glycoproteins
Hamilton, S. R., Davidson, R. C., Sethuraman, N., Nett, J. H., Jiang, Y., Rios, S., Bobrowicz, P., Stadheim, T. A., Li, H., Choi, B.-K., et al. (2006) · Science · doi:10.1126/science.1130256 · Cited by 511
Cited by
Trends in Upstream and Downstream Process Development for Antibody Manufacturing
Gronemeyer, P., Ditz, R., & Strube, J. (2014) · Bioengineering · doi:10.3390/bioengineering1040188 · Cited by 329
O’Flaherty, R., Bergin, A., Flampouri, E., Mota, L. M., Obaidi, I., Quigley, A., Xie, Y., & Butler, M. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2020.107552 · Cited by 277
Eon‐Duval, A., Broly, H., & Gleixner, R. (2012) · Biotechnology Progress · doi:10.1002/btpr.1548 · Cited by 234
The choice of mammalian cell host and possibilities for glycosylation engineering
Butler, M., & Spearman, M. (2014) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2014.06.010 · Cited by 175
“com process of ‘Quality by Design (QBD)’ to ensure consistent and targeted glycan micro-heterogeneity and macroheterogeneity [2,3].”
BackgroundReusch, D., Haberger, M., Maier, B., Maier, M., Kloseck, R., Zimmermann, B., Hook, M., Szabo, Z., Tep, S., Wegstein, J., et al. (2015) · mAbs · doi:10.4161/19420862.2014.986000 · Cited by 168
Jimenez del Val, I., Nagy, J. M., & Kontoravdi, C. (2011) · Biotechnology Progress · doi:10.1002/btpr.688 · Cited by 135
Self-citationJedrzejewski, P., Del Val, I., Constantinou, A., Dell, A., Haslam, S., Polizzi, K., & Kontoravdi, C. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15034492 · Cited by 83
Self-citationProteins behaving badly: emerging technologies in profiling biopharmaceutical aggregation
Hamrang, Z., Rattray, N. J. W., & Pluen, A. (2013) · Trends in Biotechnology · doi:10.1016/j.tibtech.2013.05.004 · Cited by 75
Kornecki, M., & Strube, J. (2018) · Bioengineering · doi:10.3390/bioengineering5010025 · Cited by 61
“, structure, post-translational modifications, and efficacy) [7,8].”
Toward Biotherapeutic Product Real‐Time Quality Monitoring
Guerra, A., von Stosch, M., & Glassey, J. (2019) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2018.1524362 · Cited by 58
“tions correlate process heterogeneity with the variability of the metabolic state [35,37] or CQAs [38,39].”
BackgroundEngineering Challenges in Therapeutic Protein Product and Process Design
Papathanasiou, M. M., & Kontoravdi, C. (2020) · Current Opinion in Chemical Engineering · doi:10.1016/j.coche.2019.11.010 · Cited by 57
Self-citationGraf, T., Heinrich, K., Grunert, I., Wegele, H., Haberger, M., Bulau, P., & Leiss, M. (2020) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2020.113251 · Cited by 46
del Val, I. J., Kyriakopoulos, S., Polizzi, K. M., & Kontoravdi, C. (2013) · Analytical Biochemistry · doi:10.1016/j.ab.2013.09.005 · Cited by 45
Self-citationdel Val, I. J., Polizzi, K. M., & Kontoravdi, C. (2016) · Scientific Reports · doi:10.1038/srep28547 · Cited by 41
Self-citationmAb Production Modeling and Design Space Evaluation Including Glycosylation Process
Yang, O., & Ierapetritou, M. (2021) · Processes · doi:10.3390/pr9020324 · Cited by 26
Aghamohseni, H., Spearman, M., Ohadi, K., Braasch, K., Moo-Young, M., Butler, M., & Budman, H. M. (2017) · Journal of Industrial Microbiology and Biotechnology · doi:10.1007/s10295-017-1926-z · Cited by 13
Metadata
- Authors
- del Val, I. J., Kontoravdi, C., & Nagy, J. M.
- Venue
- Biotechnology Progress
- Publisher
- Wiley
- Published
- 2010-11
- Volume
- 26
- Issue
- 6
- Pages
- 1505-1527
- ISSN
- 1520-6033 (ISSN-L)
- 8756-7938
- OpenAlex
- W2102729277
- Cited by
- 139
- References
- 19
- FWCI
- 3.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.